Mavorixafor

CHEMBL518924 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

349.5 g/mol

LogP

2.4

Phase

4

A CXCR4 antagonist for WHIM syndrome.

Molekularmasse

349,5000 g/mol

LogP

2,40

TPSA

70,80 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Melanoma Breast Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21

InChI

InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1

Molecular Formula

C21H27N5

HBD / HBA

2 / 4

Rotierbare Bindungen

7

Schwere Atome

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A CXCR4 antagonist for WHIM syndrome.

Yes, Mavorixafor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL518924. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11256587. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Mavorixafor auf PillFYI

Struktur

Schnelldaten

Formel: C21H27N5
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.